These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

213 related items for PubMed ID: 23466871

  • 21. Extra-thoracic tumor burden but not thoracic tumor burden on (18)F-FDG PET/CT is an independent prognostic biomarker for extensive-disease small cell lung cancer.
    Oh JR, Seo JH, Hong CM, Jeong SY, Lee SW, Lee J, Min JJ, Song HC, Bom HS, Kim YC, Ahn BC.
    Lung Cancer; 2013 Aug; 81(2):218-25. PubMed ID: 23731740
    [Abstract] [Full Text] [Related]

  • 22. A pilot study on EORTC or PERCIST for the prediction of progression-free survival with nivolumab therapy in advanced or metastatic gastric cancers: A STROBE-compliant article.
    Nakajo M, Kitajima K, Toriihara A, Arigami T, Daisaki H, Nakamura A, Ohtsuka T, Miwa H, Yoshiura T.
    Medicine (Baltimore); 2021 Apr 16; 100(15):e25494. PubMed ID: 33847661
    [Abstract] [Full Text] [Related]

  • 23. Prognostic significance of standardised uptake value (SUVmax ) measured on 18F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with small cell lung cancer.
    Yilmaz Demirci N, Yilmaz Ü, Biner Uslu I, Dikmen A, Yılmaz A, Erdoğan Y.
    Eur J Cancer Care (Engl); 2017 Sep 16; 26(5):. PubMed ID: 26988938
    [Abstract] [Full Text] [Related]

  • 24. The predictive value of 18F-FDG PET-CT for assessing the clinical outcomes in locally advanced NSCLC patients after a new induction treatment: low-dose fractionated radiotherapy with concurrent chemotherapy.
    Mattoli MV, Massaccesi M, Castelluccia A, Scolozzi V, Mantini G, Calcagni ML.
    Radiat Oncol; 2017 Jan 05; 12(1):4. PubMed ID: 28057034
    [Abstract] [Full Text] [Related]

  • 25. Evaluation of response to stereotactic body radiation therapy for nonsmall cell lung cancer: PET response criteria in solid tumors versus response evaluation criteria in solid tumors.
    Han J, Song Q, Guo F, Du R, Fang H, Kang J, Lu Z.
    Nucl Med Commun; 2022 Jun 01; 43(6):717-724. PubMed ID: 35354781
    [Abstract] [Full Text] [Related]

  • 26. Prognostic significance of metabolic parameters measured by 18F-FDG PET/CT in limited-stage small-cell lung carcinoma.
    Chang H, Lee SJ, Lim J, Lee JS, Kim YJ, Lee WW.
    J Cancer Res Clin Oncol; 2019 May 01; 145(5):1361-1367. PubMed ID: 30900157
    [Abstract] [Full Text] [Related]

  • 27. Whole-body metabolic tumour volume of 18F-FDG PET/CT improves the prediction of prognosis in small cell lung cancer.
    Oh JR, Seo JH, Chong A, Min JJ, Song HC, Kim YC, Bom HS.
    Eur J Nucl Med Mol Imaging; 2012 Jun 01; 39(6):925-35. PubMed ID: 22270509
    [Abstract] [Full Text] [Related]

  • 28. Comparison of prognostic value of different metabolic response criteria determined by PET/CT in patients with metastatic breast cancer under CDK 4/6 inhibitor treatment.
    Önner H, Eren OÖ, Körez MK, Yilmaz F, Kara Gedik G.
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2023 Jun 01; 42(5):319-324. PubMed ID: 37030597
    [Abstract] [Full Text] [Related]

  • 29. The role of interim 18F-FDG PET/CT in prediction of response to ipilimumab treatment in metastatic melanoma.
    Sachpekidis C, Anwar H, Winkler J, Kopp-Schneider A, Larribere L, Haberkorn U, Hassel JC, Dimitrakopoulou-Strauss A.
    Eur J Nucl Med Mol Imaging; 2018 Jul 01; 45(8):1289-1296. PubMed ID: 29478079
    [Abstract] [Full Text] [Related]

  • 30. Assessment of tumor response to chemoradiotherapy and predicting prognosis in patients with head and neck squamous cell carcinoma by PERCIST.
    Katsuura T, Kitajima K, Fujiwara M, Terada T, Uwa N, Noguchi K, Doi H, Tamaki Y, Yoshida R, Tsuchitani T, Fujita M, Yamakado K.
    Ann Nucl Med; 2018 Aug 01; 32(7):453-462. PubMed ID: 29858797
    [Abstract] [Full Text] [Related]

  • 31. [Efficacy of fluoro-2-deoxyglucose positron emission tomography imaging in response evaluation of patients with small cell lung cancer (pilot study)].
    Isobe K, Kaburaki K, Sakaguchi S, Takai Y, Hata Y, Homma S.
    Nihon Kokyuki Gakkai Zasshi; 2009 Dec 01; 47(12):1077-81. PubMed ID: 20058682
    [Abstract] [Full Text] [Related]

  • 32. Assessment of tumor response to definitive chemoradiotherapy and prognosis prediction in patients with esophageal cancer judged by PET response criteria in solid tumors: multicenter study in Japan.
    Kitajima K, Kaida H, Nakatani K, Ishibashi M, Morita T, Nakajo M, Tamaki Y, Minamimoto R.
    Nucl Med Commun; 2020 May 01; 41(5):443-451. PubMed ID: 32187159
    [Abstract] [Full Text] [Related]

  • 33. Comparison of modified Response Evaluation Criteria in Solid Tumors, European Organization for Research and Treatment of Cancer criteria, and PET Response Criteria in Solid Tumors for evaluation of tumor response to chemotherapy and prognosis prediction in patients with unresectable malignant pleural mesothelioma.
    Kitajima K, Maruyama M, Minami T, Yokoi T, Kuribayashi K, Kijima T, Hashimoto M, Hasegawa S, Yamakado K.
    Nucl Med Commun; 2020 Aug 01; 41(8):790-799. PubMed ID: 32516245
    [Abstract] [Full Text] [Related]

  • 34. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
    Zhang H, Wroblewski K, Liao S, Kampalath R, Penney BC, Zhang Y, Pu Y.
    Acad Radiol; 2013 Jan 01; 20(1):32-40. PubMed ID: 22999369
    [Abstract] [Full Text] [Related]

  • 35. The clinical value of PERCIST to predict tumour response and prognosis of patients with oesophageal cancer treated by neoadjuvant chemoradiotherapy.
    Nakajo M, Kitajima K, Kaida H, Morita T, Minamimoto R, Ishibashi M, Yoshiura T.
    Clin Radiol; 2020 Jan 01; 75(1):79.e9-79.e18. PubMed ID: 31662200
    [Abstract] [Full Text] [Related]

  • 36. Predictive and Prognostic Value of Early Disease Progression by PET Evaluation in Advanced Non-Small Cell Lung Cancer.
    Banna GL, Anile G, Russo G, Vigneri P, Castaing M, Nicolosi M, Strano S, Gieri S, Spina R, Patanè D, Calcara G, Fraggetta F, Marletta F, Stefano A, Ippolito M.
    Oncology; 2017 Jan 01; 92(1):39-47. PubMed ID: 27832654
    [Abstract] [Full Text] [Related]

  • 37. Prognostic significance of metabolic parameters measured by (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with small cell lung cancer.
    Zhu D, Ma T, Niu Z, Zheng J, Han A, Zhao S, Yu J.
    Lung Cancer; 2011 Sep 01; 73(3):332-7. PubMed ID: 21292341
    [Abstract] [Full Text] [Related]

  • 38. Comparative analysis of different response criteria at early phase after PD-1 blockade in non-small lung cancer.
    Kaira K, Yamaguchi O, Naruse I, Umeda Y, Honda T, Watanabe S, Ichikawa K, Yanagisawa S, Kasahara N, Higuchi T, Hashimoto K, Miura Y, Shiono A, Mouri A, Imai H, Iizuka K, Ishizuka T, Minato K, Suda S, Kagamu H, Mori K, Seki N, Kuji I.
    Cancer Imaging; 2023 Mar 01; 23(1):23. PubMed ID: 36859341
    [Abstract] [Full Text] [Related]

  • 39. 18F-FDG PET/CT for monitoring anti-PD-1 therapy in patients with non-small cell lung cancer using SUV harmonization of results obtained with various types of PET/CT scanners used at different centers.
    Ito K, Kitajima K, Toriihara A, Ishibashi M, Nakahara T, Daisaki H, Ohe Y, Honda R, Kijima T, Hasegawa S, Nakajo M.
    Ann Nucl Med; 2021 Nov 01; 35(11):1253-1263. PubMed ID: 34370219
    [Abstract] [Full Text] [Related]

  • 40. PET/CT evaluation of response to chemotherapy in non-small cell lung cancer: PET response criteria in solid tumors (PERCIST) versus response evaluation criteria in solid tumors (RECIST).
    Ding Q, Cheng X, Yang L, Zhang Q, Chen J, Li T, Shi H.
    J Thorac Dis; 2014 Jun 01; 6(6):677-83. PubMed ID: 24976990
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.